Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS - Related Studies

Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS

This study has been completed.

Study NCT00002940. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma

2	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

3	Interventions listed in this trial
		hydroxyurea

4	More general drug interventions related to this trial
		Antineoplastic Agents
		Antisickling Agents
		Enzyme Inhibitors
		Hematologic Agents
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Therapeutic Uses

5	Sponsors listed in this trial
		St. Jude Children's Research Hospital